Palo Alto, Calif.-based Theranos is able to continue operating its Scottsdale lab because it is appealing the lab certificate revocation, according to the report, which effectively stalls the lab’s shutdown. It could be months or even years before the appeal is settled, as a review of past case documents on the HHS website indicate some certificate-revocation appeals have dragged on for more than three years, AZ Central reported.
Meanwhile, Theranos officials said they amended the company’s lab operations to address the deficiencies that led to sanctions by CMS. The company said it “has made substantial progress toward correcting the deficiencies CMS identified, including appointing new laboratory leadership, enhancing Theranos’ clinical policies and procedures and revamping training programs,” according to the report.
Company officials added Theranos plans to continue talks with federal lab regulators “regarding the possibility of reaching a mutually agreeable resolution to this matter,” according to the report.
More articles on quality:
Top 6 North Carolina hospitals patients would definitely recommend
HHS partners with 2 pharma companies to create new antibiotics
Zika labs get boost from CDC
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
